Vimarsana
Biggest News Aggregation in the World

Page 2 - Current Standard News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Current Standard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Current Standard Today - Breaking & Trending Today

Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment - Vimarsana News

Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

The expert panel highlights the psychosocial burden of alopecia areata on patients and discusses the current treatment paradigm.

NLRB's Latest Move to Support Unions During Bargaining - Vimarsana News

NLRB's Latest Move to Support Unions During Bargaining

The Division of Advice within the National Labor Relations Board’s Office of the General Counsel urged the NLRB to overturn existing law to lower the standard for when an employer must furnish the union with its general financial information. This would give unions more power.

NLRB General Counsel Proposes Lower Standard For Requiring Employers to Provide Financial Information | Epstein Becker & Green - Vimarsana News

NLRB General Counsel Proposes Lower Standard For Requiring Employers to Provide Financial Information | Epstein Becker & Green

In an Advice Memorandum dated April 20, 2022 and released on November 30, 2022, the Division of Advice within the National Labor Relations Board’s (“NLRB” or “Board”) Office of the...

Olympus Awarded Bronchoscopy Solutions Agreement with Premier, Inc. - Vimarsana News

Olympus Awarded Bronchoscopy Solutions Agreement with Premier, Inc.

/PRNewswire/ -- Olympus today announced it has been awarded a group purchasing agreement in the Single-Use Visualization Devices category for its single-use...

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA - Vimarsana News

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI